Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 851 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo TID Clear all
Completed Phase 2 Interventional

Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain

NCT02104050
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo Gel, OLT1177 Gel
Drug
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Milford, Connecticut • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
View directory record Official record
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 11, 2026, 2:05 PM EDT
Active, not recruiting Phase 2 Interventional

Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

NCT05928390
View directory record Official record
Conditions
Post-Bariatric Hypoglycemia
Interventions
Pasireotide Diaspartate
Drug
Lead sponsor
RECORDATI GROUP
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Palo Alto, California • Chicago, Illinois • Metairie, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 11, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

NCT02372578
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy (PDPN)
Interventions
ASP3662, pregabalin, ASP3662 placebo, pregabalin placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
37
States / cities
Anniston, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects

NCT01706315
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 11, 2026, 2:05 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy

NCT04378075
View directory record Official record
Conditions
Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome
Interventions
Vatiquinone, Placebo
Drug · Other
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Up to 20 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
San Diego, California • Stanford, California • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Emphysema
Interventions
sildenafil citrate, Placebo
Drug
Lead sponsor
Kawut, Steven, MD
Individual
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Effects of Acipimox on Mitochondrial Function in Obesity

NCT01488409
View directory record Official record
Conditions
Abdominal Obesity, Insulin Resistance, Hypertriglyceridemia
Interventions
Acipimox, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses

NCT03752307
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Isoxsuprine Hydrochloride, Placebo, Corticosteroid
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 11, 2026, 2:05 PM EDT
Withdrawn Phase 2 Interventional

Rifaximin Treatment of Papulopustular Rosacea

NCT01359228
View directory record Official record
Conditions
Rosacea
Interventions
Rifaximin (XIFAXAN), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2014 · Synced Sep 11, 2026, 2:05 PM EDT
Recruiting Phase 2 Interventional

Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression

NCT06263660
View directory record Official record
Conditions
Depression
Interventions
Keto-like supplement, Placebo
Dietary Supplement
Lead sponsor
Laureate Institute for Brain Research, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases

NCT00001723
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Metabolic Disease, Obesity, Sleep Apnea Syndrome
Interventions
Orlistat, Placebo
Drug
Lead sponsor
Jack Yanovski
NIH
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Not applicable Interventional

Evaluation of Open-Label Conditioned Placebo Analgesia for Postoperative Opioid Reduction Following Spinal Fusion

NCT04574388
View directory record Official record
Conditions
Spine Surgery
Interventions
open label placebo
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2021 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

NCT01280344
View directory record Official record
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 11, 2026, 2:05 PM EDT
Terminated Phase 3 Interventional Results available

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy

NCT04639310
View directory record Official record
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Orange, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder

NCT02395978
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PDC-1421 Capsule, placebo
Drug
Lead sponsor
BioLite, Inc.
Industry
Eligibility
20 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 11, 2026, 2:05 PM EDT
Terminated Phase 2 Interventional

Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

NCT00690885
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Cough
Interventions
interferon-alpha lozenges, placebo lozenges
Drug
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
40 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Results available

Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

NCT03154476
View directory record Official record
Conditions
Cirrhosis, Congenital Heart Disease
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

NCT02355886
View directory record Official record
Conditions
Bladder Carcinoma
Interventions
Gabapentin, Placebo, Questionnaire Administration
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 11, 2026, 2:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder

NCT06559995
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal, Ketosis
Interventions
ketone supplement "D-beta-hydroxybutryric acid and R-1,3 butanediol" 12g of ketones,, magnetic resonance imaging session, Placebo beverage
Dietary Supplement · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional

Tetracycline Treatment Tolerability Trial

NCT05219929
View directory record Official record
Conditions
Post-Treatment Lyme Disease
Interventions
Tetracycline 500 Mg, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 11, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

St. John's Wort for Tobacco Cessation

NCT00405912
View directory record Official record
Conditions
Smoking, Nicotine Dependence
Interventions
Placebo, St. John's Wort-900 mg/day, St. John's Wort-1800mg/day
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 11, 2026, 2:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Droxidopa, Atenolol, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 11, 2026, 2:05 PM EDT